Hostname: page-component-77c78cf97d-hf2s2 Total loading time: 0 Render date: 2026-04-24T04:39:13.775Z Has data issue: false hasContentIssue false
  • English
  • Français

Prevalence and Predictors of Postdischarge Antibiotic Use Following Mastectomy

Published online by Cambridge University Press:  03 July 2017

Margaret A. Olsen ,
Katelin B. Nickel ,
Victoria J. Fraser ,
Anna E. Wallace  and
David K. Warren
Margaret A. Olsen*
Affiliation:
Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St Louis, Missouri Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri
Katelin B. Nickel
Affiliation:
Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St Louis, Missouri
Victoria J. Fraser
Affiliation:
Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St Louis, Missouri
Anna E. Wallace
Affiliation:
HealthCore, Inc, Wilmington, Delaware
David K. Warren
Affiliation:
Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St Louis, Missouri
*
Address correspondence to Margaret A. Olsen, PhD, MPH, Washington University School of Medicine, Division of Infectious Diseases, 4523 Clayton Ave, Campus Box 8051, St Louis, MO 63110 (molsen@wustl.edu).
Get access Rights & Permissions [Opens in a new window]

Abstract

OBJECTIVE

Survey results suggest that prolonged administration of prophylactic antibiotics is common after mastectomy with reconstruction. We determined utilization, predictors, and outcomes of postdischarge prophylactic antibiotics after mastectomy with or without immediate breast reconstruction.

DESIGN

Retrospective cohort.

PATIENTS

Commercially insured women aged 18–64 years coded for mastectomy from January 2004 to December 2011 were included in the study. Women with a preexisting wound complication or septicemia were excluded.

METHODS

Predictors of prophylactic antibiotics within 5 days after discharge were identified in women with 1 year of prior insurance enrollment; relative risks (RR) were calculated using generalized estimating equations.

RESULTS

Overall, 12,501 mastectomy procedures were identified; immediate reconstruction was performed in 7,912 of these procedures (63.3%). Postdischarge prophylactic antibiotics were used in 4,439 procedures (56.1%) with immediate reconstruction and 1,053 procedures (22.9%) without immediate reconstruction (P<.001). The antibiotics most commonly prescribed were cephalosporins (75.1%) and fluoroquinolones (11.1%). Independent predictors of postdischarge antibiotics were implant reconstruction (RR, 2.41; 95% confidence interval [CI], 2.23–2.60), autologous reconstruction (RR, 2.17; 95% CI, 1.93–2.45), autologous reconstruction plus implant (RR, 2.11; 95% CI, 1.92–2.31), hypertension (RR, 1.05; 95% CI, 1.00–1.10), tobacco use (RR, 1.07; 95% CI, 1.01–1.14), surgery at an academic hospital (RR, 1.14; 95% CI, 1.07–1.21), and receipt of home health care (RR, 1.11; 95% CI, 1.04–1.18). Postdischarge prophylactic antibiotics were not associated with SSI after mastectomy with or without immediate reconstruction (both P>.05).

CONCLUSIONS

Prophylactic postdischarge antibiotics are commonly prescribed after mastectomy; immediate reconstruction is the strongest predictor. Stewardship efforts in this population to limit continuation of prophylactic antibiotics after discharge are needed to limit antimicrobial resistance.

Infect Control Hosp Epidemiol 2017;38:1048–1054

Information

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 38 , Issue 9 , September 2017 , pp. 1048 - 1054
Copyright
© 2017 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

PREVIOUS PRESENTATION. This work was presented at the International Conference on Pharmacoepidemiology and Therapeutic Risk Management in Dublin, Ireland, on August 26, 2016.

References

REFERENCES

1. Magill, SS, Edwards, JR, Bamberg, W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014;370:1198–1208.Google Scholar
2. Mangram, AJ, Horan, TC, Pearson, ML, Silver, LC, Jarvis, WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999;20:250–278.Google Scholar
3. Berrios-Torres, SI, Umscheid, CA, Bratzler, DW, et al. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg 2017. doi: 10.1001/jamasurg.2017.0904.Google Scholar
4. Bratzler, DW, Dellinger, EP, Olsen, KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013;70:195–283.Google Scholar
5. Systematic review and evidence-based guidance on perioperative antibiotic prophylaxis. European Centre for Disease Prevention and Control website. http://ecdc.europa.eu/en/publications/Publications/Perioperative%20antibiotic%20prophylaxis%20-%20June%202013.pdf. Published 2013. Accessed June 16, 2016.Google Scholar
6. Ingraham, AM, Cohen, ME, Bilimoria, KY, et al. Association of surgical care improvement project infection-related process measure compliance with risk-adjusted outcomes: implications for quality measurement. J Am Coll Surg 2010;211:705–714.Google Scholar
7. Wang, Z, Chen, F, Ward, M, Bhattacharyya, T. Compliance with surgical care improvement project measures and hospital-associated infections following hip arthroplasty. J Bone Joint Surg Am 2012;94:1359–1366.Google Scholar
8. Harbarth, S, Samore, MH, Lichtenberg, D, Carmeli, Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000;101:2916–2921.Google Scholar
9. Poeran, J, Mazumdar, M, Rasul, R, et al. Antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2016;151:589–597.Google Scholar
10. Throckmorton, AD, Boughey, JC, Boostrom, SY, et al. Postoperative prophylactic antibiotics and surgical site infection rates in breast surgery patients. Ann Surg Oncol 2009;16:2464–2469.Google Scholar
11. Hedrick, TL, Smith, PW, Gazoni, LM, Sawyer, RG. The appropriate use of antibiotics in surgery: a review of surgical infections. Curr Probl Surg 2007;44:635–675.Google Scholar
12. Halvorson, EG, Disa, JJ, Mehrara, BJ, Burkey, BA, Pusic, AL, Cordeiro, PG. Outcome following removal of infected tissue expanders in breast reconstruction: a 10-year experience. Ann Plast Surg 2007;59:131–136.Google Scholar
13. Macadam, SA, Clugston, PA, Germann, ET. Retrospective case review of capsular contracture after two-stage breast reconstruction: is colonization of the tissue expander pocket associated with subsequent implant capsular contracture? Ann Plast Surg 2004;53:420–424.Google Scholar
14. Khan, UD. Breast augmentation, antibiotic prophylaxis, and infection: comparative analysis of 1,628 primary augmentation mammoplasties assessing the role and efficacy of antibiotics prophylaxis duration. Aesthetic Plast Surg 2010;34:42–47.Google Scholar
15. Perrotti, JA, Castor, SA, Perez, PC, Zins, JE. Antibiotic use in aesthetic surgery: a national survey and literature review. Plast Reconstr Surg 2002;109:1685–1693.CrossRefGoogle ScholarPubMed
16. Alderman, A, Gutowski, K, Ahuja, A, Gray, D. ASPS clinical practice guideline summary on breast reconstruction with expanders and implants. Plast Reconstr Surg 2014;134:648e–655e.CrossRefGoogle ScholarPubMed
17. Phillips, BT, Wang, ED, Mirrer, J, et al. Current practice among plastic surgeons of antibiotic prophylaxis and closed-suction drains in breast reconstruction: experience, evidence, and implications for postoperative care. Ann Plast Surg 2011;66:460–465.Google Scholar
18. Chopra, K, Gowda, AU, McNichols, CH, Brown, EN, Slezak, S, Rasko, Y. Antimicrobial prophylaxis practice patterns in breast augmentation: a national survey of current practice. Ann Plast Surg 2016.Google Scholar
19. Olsen, MA, Nickel, KB, Fox, IK, et al. Incidence of surgical site infection following mastectomy with and without immediate reconstruction using private insurer claims data. Infect Control Hosp Epidemiol 2015;36:907–914.Google Scholar
20. Olsen, MA, Nickel, KB, Margenthaler, JA, et al. Development of a risk prediction model to individualize risk factors for surgical site infection after mastectomy. Ann Surg Oncol 2016;23:2471–2479.Google Scholar
21. Nickel, KB, Fox, IK, Margenthaler, JA, Wallace, AE, Fraser, VJ, Olsen, MA. Effect of noninfectious wound complications after mastectomy on subsequent surgical procedures and early implant loss. J Am Coll Surg 2016;222:844–852.Google Scholar
22. Elixhauser, A, Steiner, C, Harris, R, Coffey, RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8–27.Google Scholar
23. Brahmbhatt, RD, Huebner, M, Scow, JS, et al. National practice patterns in preoperative and postoperative antibiotic prophylaxis in breast procedures requiring drains: survey of the american society of breast surgeons. Ann Surg Oncol 2012;19:3205–3211.Google Scholar
24. Sartelli, M, Duane, TM, Catena, F, et al. Antimicrobial stewardship: a call to action for surgeons. Surg Infect (Larchmt) 2016;17:625–631.Google Scholar
25. Serletti, JM, Fosnot, J, Nelson, JA, Disa, JJ, Bucky, LP. Breast reconstruction after breast cancer. Plast Reconstr Surg 2011;127:124e–135e.Google Scholar
26. Clayton, JL, Bazakas, A, Lee, CN, Hultman, CS, Halvorson, EG. Once is not enough: withholding postoperative prophylactic antibiotics in prosthetic breast reconstruction is associated with an increased risk of infection. Plast Reconstr Surg 2012;130:495–502.CrossRefGoogle Scholar
27. Edwards, BL, Stukenborg, GJ, Brenin, DR, Schroen, AT. Use of prophylactic postoperative antibiotics during surgical drain presence following mastectomy. Ann Surg Oncol 2014;21:3249–3255.Google Scholar
28. Avashia, YJ, Mohan, R, Berhane, C, Oeltjen, JC. Postoperative antibiotic prophylaxis for implant-based breast reconstruction with acellular dermal matrix. Plast Reconstr Surg 2013;131:453–461.Google Scholar
29. Liu, DZ, Dubbins, JA, Louie, O, Said, HK, Neligan, PC, Mathes, DW. Duration of antibiotics after microsurgical breast reconstruction does not change surgical infection rate. Plast Reconstr Surg 2012;129:362–367.CrossRefGoogle Scholar
30. McCullough, MC, Chu, CK, Duggal, CS, Losken, A, Carlson, GW. Antibiotic prophylaxis and resistance in surgical site infection after immediate tissue expander reconstruction of the breast. Ann Plast Surg 2016;77:501–505.Google Scholar
31. Townley, WA, Baluch, N, Bagher, S, et al. A single pre-operative antibiotic dose is as effective as continued antibiotic prophylaxis in implant-based breast reconstruction: a matched cohort study. J Plast Reconstr Aesthet Surg 2015;68:673–678.Google Scholar
32. Drury, KE, Lanier, ST, Khavanin, N, et al. Impact of postoperative antibiotic prophylaxis duration on surgical site infections in autologous breast reconstruction. Ann Plast Surg 2016;76:174–179.Google Scholar
33. Phillips, BT, Fourman, MS, Bishawi, M, et al. Are prophylactic postoperative antibiotics necessary for immediate breast reconstruction? Results of a prospective randomized clinical trial. J Am Coll Surg 2016;222:1116–1124.Google Scholar
34. Olsen, MA, Nickel, KB, Fox, IK. Surveillance and prevention of surgical site infections in breast oncologic surgery with immediate reconstruction. Curr Treat Options Infect Dis 2017.Google Scholar
35. Paterson, DL. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004;38(Suppl 4):S341–S345.Google Scholar
36. Wise, BL, Peloquin, C, Choi, H, Lane, NE, Zhang, Y. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med 2012;125:1228.e1223–1228.e1228.Google Scholar
37. Lapi, F, Wilchesky, M, Kezouh, A, Benisty, JI, Ernst, P, Suissa, S. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis 2012;55:1457–1465.Google Scholar
38. Etminan, M, Brophy, JM, Samii, A. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. Neurology 2014;83:1261–1263.Google Scholar
39. Olsen, MA, Fraser, VJ. Use of diagnosis codes and/or wound culture results for surveillance of surgical site infection after mastectomy and breast reconstruction. Infect Control Hosp Epidemiol 2010;31:544–547.Google Scholar
40. Dubberke, ER, Butler, AM, Yokoe, DS, et al. Multicenter study of surveillance for hospital-onset Clostridium difficile infection by the use of ICD-9-CM diagnosis codes. Infect Control Hosp Epidemiol 2010;31:262–268.CrossRefGoogle ScholarPubMed
41. Jagsi, R, Jiang, J, Momoh, AO, et al. Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States. J Clin Oncol 2014;32:919–926.Google Scholar
Supplementary material: File

Olsen supplementary material

Appendix

Download Olsen supplementary material(File)
File 31.2 KB